Sangamo Therapeutics, Inc (SGMO) SEC Filings — 2024

Filings

• Sangamo Therapeutics Terminates Material Definitive Agreement — 8-K · Dec 30, 2024
• Kite to Acquire Sangamo Therapeutics for $3.4B — 8-K · Dec 10, 2024
• Sangamo Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 12, 2024
• Sangamo Therapeutics, Inc SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• Sangamo Therapeutics, Inc SC 13G/A Filing — SC 13G/A · Nov 4, 2024
• Sangamo Therapeutics Files 8-K — 8-K · Oct 4, 2024
• Sangamo Therapeutics, Inc SC 13G/A Filing — SC 13G/A · Aug 16, 2024
• Sangamo Therapeutics Files 8-K — 8-K · Aug 6, 2024
• Kite to Acquire Sangamo Therapeutics for $3.4B — 8-K · Jul 24, 2024
• Sangamo Therapeutics, Inc SC 13G/A Filing — SC 13G/A · Jul 8, 2024
• Sangamo Therapeutics Announces Corporate Changes — 8-K · Jun 5, 2024
• Sangamo Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024
• Sangamo Therapeutics Faces Nasdaq Delisting Warning — 8-K · Apr 30, 2024
• Sangamo Therapeutics Sets June 4th Virtual Annual Meeting — DEF 14A · Apr 19, 2024
• Sangamo Therapeutics, Inc SC 13G/A Filing — SC 13G/A · Apr 5, 2024
• Sangamo Therapeutics Closes $55.2M Public Offering — 8-K · Mar 25, 2024
• Sangamo Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 13, 2024
• Vanguard Adjusts Sangamo Therapeutics Stake to 6.9% — SC 13G/A · Feb 13, 2024
• BIOGEN AMENDS SANGAMO STAKE: Ownership Change as of Dec 31, 2023 — SC 13G/A · Feb 12, 2024
• Wasatch Advisors LP Maintains 7.0% Stake in Sangamo Therapeutics — SC 13G/A · Feb 9, 2024
• Sangamo Therapeutics Files 8-K for 'Other Event' on Feb 5 — 8-K · Feb 6, 2024
• BlackRock Amends Sangamo Therapeutics Stake (SC 13G/A) — SC 13G/A · Jan 26, 2024
• State Street Exits Sangamo Therapeutics Stake — SC 13G/A · Jan 22, 2024
• Sangamo Therapeutics Updates Principal Executive Office Address — 8-K · Jan 19, 2024